419 related articles for article (PubMed ID: 15732524)
1. Prospects for a group A streptococcal vaccine.
McMillan DJ; Chhatwal GS
Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
[TBL] [Abstract][Full Text] [Related]
4. Group A streptococcal vaccines: facts versus fantasy.
Steer AC; Batzloff MR; Mulholland K; Carapetis JR
Curr Opin Infect Dis; 2009 Dec; 22(6):544-52. PubMed ID: 19797947
[TBL] [Abstract][Full Text] [Related]
5. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?
Smeesters PR; McMillan DJ; Sriprakash KS; Georgousakis MM
Expert Rev Vaccines; 2009 Dec; 8(12):1705-20. PubMed ID: 19905872
[TBL] [Abstract][Full Text] [Related]
6. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
[TBL] [Abstract][Full Text] [Related]
7. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS.
Smeesters PR; Dramaix M; Van Melderen L
Vaccine; 2010 Jan; 28(4):883-5. PubMed ID: 19963033
[No Abstract] [Full Text] [Related]
8. Host-pathogen interactions in Streptococcus pyogenes infections, with special reference to puerperal fever and a comment on vaccine development.
Areschoug T; Carlsson F; Stålhammar-Carlemalm M; Lindahl G
Vaccine; 2004 Dec; 22 Suppl 1():S9-S14. PubMed ID: 15576204
[TBL] [Abstract][Full Text] [Related]
9. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
Tsoi SK; Smeesters PR; Frost HR; Licciardi P; Steer AC
J Immunol Res; 2015; 2015():167089. PubMed ID: 26101780
[TBL] [Abstract][Full Text] [Related]
10. Group A streptococcus epidemiology and vaccine implications.
Cohen-Poradosu R; Kasper DL
Clin Infect Dis; 2007 Oct; 45(7):863-5. PubMed ID: 17806050
[No Abstract] [Full Text] [Related]
11. Immunity to group a streptococcal M proteins: forging a single-edged sword.
Madoff LC
Clin Infect Dis; 2005 Oct; 41(8):1123-4. PubMed ID: 16163630
[No Abstract] [Full Text] [Related]
12. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
13. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
Good MF; Pandey M; Batzloff MR; Tyrrell GJ
Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
[TBL] [Abstract][Full Text] [Related]
14. The quest for GAS vaccine.
Pandey M; Good MF
Oncotarget; 2015 Oct; 6(33):34063-4. PubMed ID: 26485764
[No Abstract] [Full Text] [Related]
15. [Primary prevention of rheumatism: the status and outlook (vaccine)].
Rotta Y
Ter Arkh; 1985; 57(11):97-100. PubMed ID: 3909476
[No Abstract] [Full Text] [Related]
16. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
17. Vaccine strategies to prevent rheumatic fever.
Brandt ER; Good MF
Immunol Res; 1999; 19(1):89-103. PubMed ID: 10374697
[TBL] [Abstract][Full Text] [Related]
18. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
19. Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein.
Georgousakis MM; Hofmann A; Batzloff MR; McMillan DJ; Sriprakash KS
Vaccine; 2009 Nov; 27(48):6799-806. PubMed ID: 19729086
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis of group A streptococci in mice and efficacy of locally administered streptococcal vaccines.
Bronze MS; McKinsey DS; Beachey EH; Dale JB
Trans Assoc Am Physicians; 1988; 101():88-92. PubMed ID: 3077732
[No Abstract] [Full Text] [Related]
[Next] [New Search]
